Create a free account to unlock these features!
Create a free account to unlock these features!
| Overview | News | Financials | People | Insider Trades | Compensation | Holdings | Ownership | Corporate Family |
| Name: | Amgen Inc |
| Industries: | Biotech |
| Revenue: | $14.64B ¹ |
| Profit: | $5.18B ¹ |
| Employees: | 16,700 |
| Headquarters: | ONE AMGEN CENTER DRIVE MAIL STOP 24-1-B THOUSAND OAKS, California 91320-1799 United States Of America |
| Website: | |
| Lists: |
| #80 | Highest Market Cap |
| #58 | Best Performers |
| #3 | Best Performers In Biotech |
Discovering the future of medicine! Founded in 1980 and based in Thousand Oaks, CA, Amgen Inc. (NASDAQ: AMGN) discovers, develops, produces and markets therapeutics in cellular and molecular biology. Key products include Epogen and Aranesp, which stimulate red blood cell production; Neulasta and Neupogen, which stimulate white blood cell production; and Enbrel, which is used to treat rheumatoid arthritis and psoriasis. Its sales and marketing force operates primarily in the US, Europe and Canada.
Discovering the future of medicine! Founded in 1980 and based in Thousand Oaks, CA, Amgen Inc. (NASDAQ: AMGN) discovers, develops, produces and markets therapeutics in cellular and molecular biology. Key products include Epogen and Aranesp, which stimulate red blood cell production; Neulasta and Neupogen, which stimulate white blood cell production; and Enbrel, which is used to treat rheumatoid arthritis and psoriasis. Its sales and marketing force operates primarily in the US, Europe and Canada. The company had 2008 revenue of about $15 billion and has about 16,700 employees.
|
55 min: |
How Will Obama-Care Play Into The Markets And ETFs?
|
|
|
|
3/18/10: |
Build Up Your Influence
|
|
|
|
3/18/10: |
Teva comes out on top with $7.4B Ratiopharm bid
|
|
|
|
3/17/10: |
The Healthcare ETF (XLV) Is Seeing Above Average Call Buying
|
|
|
|
3/15/10: |
GSK Drug Gets EC Approval - Analyst Blog
|
|
|
|
3/15/10: |
Amgen – A Profitable Biotech at a Bargain Price
|
|
|
|
3/12/10: |
Swedish Orphan Biovitrum AB Has Agreed To An Additional Kineret(R)
...
|
|
|
|
3/12/10: |
Morning Movers: Citi Retreats, S&P Off on Consumer Sentiment
|
|
|
|
3/11/10: |
Investing in the Biotechnology Industry
|
|
|
|
3/9/10: |
Fitch Affirms Amgen's IDR at 'A'; Rates New Issuance 'A'; Outlook
...
|
|
| Income (in thousands of USD) |
3 months ending 2009-12-31 |
12 months ending 2009-12-31 |
| Revenue | 3,809,000 | 14,642,000 |
| Net Income | 1,509,000 | 5,183,000 |
| Balance Sheet (in thousands of USD) | ||
| Current Assets | 18,932,000 | 18,932,000 |
| Total Assets | 39,629,000 | 39,629,000 |
| Current Liabilities | 3,873,000 | 3,873,000 |
| Total Liabilities | 16,962,000 | 16,962,000 |
| Total Shareholders Equity | 22,667,000 | 22,667,000 |
| Cash Flow (in thousands of USD) | ||
| Cash from Operating Activity | 1,823,000 | 6,336,000 |
| Cash from Investing Activity | -339,000 | -3,202,000 |
| Cash from Financing Activity | -2,177,000 | -2,024,000 |
| Change in Cash | -693,000 | 1,110,000 |
| Key Stats |
3 months ending 2009-12-31 |
Trailing 12 Months |
| Gross Profit Margin | 85.88% | 85.72% |
| Net Profit Margin | 39.62% | 35.40% |
| Return on Assets | 3.81% | 13.08% |
| Return on Equity | 6.66% | 22.87% |
| Return on Invested Capital | 2.98% | 14.93% |
